Ultragenyx Pharmaceutical, Inc. (RARE)
15.57
-1.59
(-9.27%)
USD |
NASDAQ |
Nov 05, 16:00
15.30
-0.27
(-1.73%)
After-Hours: 20:00
Ultragenyx Pharmaceutical SG&A Expense (TTM) : 265.00M for Sept. 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 265.00M |
| June 30, 2026 | 351.62M |
| March 31, 2026 | 350.27M |
| December 31, 2025 | 350.06M |
| September 30, 2025 | 343.56M |
| June 30, 2025 | 337.29M |
| March 31, 2025 | 331.25M |
| December 31, 2024 | 321.61M |
| September 30, 2024 | 315.95M |
| June 30, 2024 | 310.51M |
| March 31, 2024 | 311.31M |
| December 31, 2023 | 309.80M |
| September 30, 2023 | 305.82M |
| June 30, 2023 | 300.74M |
| March 31, 2023 | 287.47M |
| December 31, 2022 | 278.14M |
| September 30, 2022 | 264.72M |
| June 30, 2022 | 248.76M |
| March 31, 2022 | 234.04M |
| December 31, 2021 | 219.98M |
| September 30, 2021 | 211.59M |
| June 30, 2021 | 199.83M |
| March 31, 2021 | 188.68M |
| December 31, 2020 | 182.93M |
| September 30, 2020 | 173.77M |
| Date | Value |
|---|---|
| June 30, 2020 | 172.65M |
| March 31, 2020 | 170.21M |
| December 31, 2019 | 161.52M |
| September 30, 2019 | 154.12M |
| June 30, 2019 | 144.21M |
| March 31, 2019 | 135.12M |
| December 31, 2018 | 127.72M |
| September 30, 2018 | 130.97M |
| June 30, 2018 | 123.37M |
| March 31, 2018 | 112.66M |
| December 31, 2017 | 99.91M |
| September 30, 2017 | 82.00M |
| June 30, 2017 | 75.68M |
| March 31, 2017 | 70.41M |
| December 31, 2016 | 64.94M |
| September 30, 2016 | 56.72M |
| June 30, 2016 | 49.77M |
| March 31, 2016 | 42.07M |
| December 31, 2015 | 33.00M |
| September 30, 2015 | 24.83M |
| June 30, 2015 | 17.58M |
| March 31, 2015 | 12.96M |
| December 31, 2014 | 10.81M |
| September 30, 2014 | 8.71M |
| June 30, 2014 | 6.728M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Ionis Pharmaceuticals, Inc. | 527.56M |
| AbbVie, Inc. | 15.19B |
| Krystal Biotech, Inc. | 122.31M |
| BridgeBio Pharma, Inc. | 709.10M |
| Alnylam Pharmaceuticals, Inc. | 1.338B |